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T cells constitute the core of adaptive cellular immunity and protect higher organisms
against pathogen infections and cancer. Monitoring of disease progression as well as
prophylactic or therapeutic vaccines and immunotherapies call for conclusive detection,
analysis, and sorting of antigen-specificT cells.This is possible by means of soluble recom-
binant ligands for T cells, i.e., MHC class I-peptide (pMHC I) complexes for CD8+ T cells
and MHC class II-peptide (pMHC II) complexes for CD4+ T cells and flow cytometry.
Here we review major developments in the development of pMHC staining reagents
and their diverse applications and discuss perspectives of their use for basic and clinical
investigations.
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INTRODUCTION
TCRαβ+ thymus derived T lymphocytes constitute the core of
adaptive cellular immunity in higher organisms and play essential
roles in their protection against pathogen infection and neoplas-
tic transformations (1). CD8+ T cells differentiate to cytotoxic
T lymphocytes (CTL) capable of efficient killing of cells display-
ing pMHC I complexes containing 8–10 residues long peptides,
derived from a pathogen or cancer (2). CD8αβ coreceptor of
CTL substantially enhances their antigen recognition, namely by
strengthening the pMHC I ligand binding and bringing CD8-
associated p56lck to the TCR/CD3 complex, thus promoting TCR
signal induction (3). In most cancer vaccines and immunother-
apies, tumor antigen-specific CD8+ T cells take center stage (4,
5). Antigen-specific CD8+ T cells can be reliably detected, ana-
lyzed, and sorted by means of soluble pMHC oligomers (6, 7).
Peptide-MHC complexes have limited life spans at 37°C and there-
fore MHC I molecules provide a dynamic display of endogenously
produced peptides. pMHC complexes can be obtained by refold-
ing of denatured heavy and light (β2m) chains in the presence of a
peptide of interest (8). This procedure is simple, inexpensive, and
yields highly pure pMHC complexes. Because the peptides bind to
MHC I molecules in a canonical manner, in which both termini
are firmly anchored in well-defined positions, these complexes are
homogenous and structurally well-defined (9).
On the other hand, CD4+ T cells differentiate from a com-
mon precursor (TH0) in different types of effector cells, such as T
help cells (Th1, Th2), or regulatory T cells (Treg). Efforts to detect
antigen-specific CD4+ T cells by soluble pMHC II multimers fared
less well than their class I counterparts for diverse reasons. MHC II
molecules consist of non-covalently linked alpha and beta chains,
both of which are transmembrane spanning proteins and their
variable domains (alpha 1 and beta 1) form an open ended pep-
tide binding groove that accommodates exogenous peptide usually
10–15 residues long (10). In contrast to MHC I, MHC II molecules,
in particular HLA II molecules, are stable without a peptide, which
allows loading of “empty” MHC II molecules with a peptide of
interest (11). Newly synthesized MHC II molecules associate with
invariant chain (li), which assists their refolding, prevents binding
of endogenous peptides in the endoplasmic reticulum, and directs
them to the endosomal/lysosomal pathway where they are loaded
with peptides generated from exogenous antigens by lysosomal
proteolytic activity (12). To prepare soluble recombinant MHC
II molecules, their transmembrane and cytoplasmic domains are
replaced by leucine zippers to prevent dissociation of the alpha and
beta chains (13). With a few exceptions pMHC II complexes can-
not be obtained in good yields by refolding and/or by mammalian
expressions systems, but can be well expressed by insect expression
systems, such as Drosophila S2 cells or SF9 cells infected with bac-
ulo virus (14, 15). While binding of soluble pMHC I complexes
to CD8+ T cells is greatly strengthened by CD8, CD4 does not
stabilize pMHC II binding to CD4+ T cells (16). Together with the
fact that CD4+ T cells usually express lower affinity than CD8+
T cells, this accounts for frequent poor pMHC II tetramer stain-
ing and missing of a substantial fraction of antigen-specific CD4+
T cells; this is often aggravated by poor reagent quality, namely
incomplete or disperse peptide loading (17).
CHRONOLOGICAL OVERVIEW OF SOLUBLE pMHC CLASS I
COMPLEXES AND THEIR USE FOR T CELL ANALYSIS
Soluble recombinant pMHC complexes are valuable tools for
investigations, analysis, and isolation of antigen-specific T cells
(Figure 1). The smallest pMHC complex is a monomer,
which according to SPR studies binds recombinant TCR with
dissociation constants (K D) in the range of 1–1000µM, and
dissociation kinetic rates in the range of 1–1500 s (18), which
precludes analysis by flow cytometry or fluorescence microscopy.
www.frontiersin.org July 2013 | Volume 4 | Article 218 | 1
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Schmidt et al. Soluble MHC-peptide complexes and antigen-specific T cells
FIGURE 1 | Evolution of soluble pMHC complexes and their applications forT cell analysis and sorting. (A) Chronological listing of milestones in the use
of pMHC complexes for the detection and analysis of antigen-specific CD8+ and CD4+ T cells. (B) Cartoons of the most frequently used pMHC oligomers; the
red oval represents PE.
Nevertheless, the binding and dissociation of monomeric pMHC
complexes was extensively studied on CD8+ CTL by means of
TCR photoaffinity labeling (19, 20). These studies revealed that
coordinate binding of CD8 to TCR-associated pMHC I com-
plexes greatly strengthens pMHC I binding, mainly by decreasing
the TCR–pMHC dissociation (3). It is noteworthy that although
pMHC binding data measured by SPR are markedly differ-
ent than those measured on living CD8+ T cells, they corre-
late well with CD8+ T cell activation. The likely explanation
for this is that intercellular TCR–pMHC interactions precede
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CD8 co-engagement, i.e., CD8 is recruited to sufficiently stable
TCR–pMHC complexes (21).
Also in 1993 pMHC I dimers were described, with the capacity
to fully activate CD8+ CTL clones, whereas monomers were inac-
tive (22). The ability of pMHC I and later also pMHC II dimers to
inhibit antigen-specific T cells in vitro and in vivo was shown to be
a promising means to block autoimmunity (23, 24). Peptide-MHC
dimers built on chemical linkers were described only many years
later (see below).
In 1996 the first pMHC I “tetramer” was described and its
usefulness demonstrated for the detection and analysis of virus-
specific CD8+ T cells (25). The subunit pMHC I monomers carry
a biotinylation sequence peptide (BSP) C-terminal of the alpha3
domain that is amenable to biotinylation with the biotin trans-
ferase BirA (26). Reaction of biotinylated pMHC I monomers with
phycoerythrin-streptavidin (PE-SA) (or allophycocyanin-SA) typ-
ically results in mixtures of pMHC I conjugates of different stoi-
chiometry and relative orientations and hence are better termed
multimers (27). Our analysis indicated that such multimers con-
tained species carrying up to 12 pMHC I monomer (unpublished
results). Real tetramers can be prepared by using “tetra-grade”
PE-SA and exhibit substantially reduced staining (see below).
In 1998 the first pMHC II multimers were described (28), which
performed less well than their pMHC I counterparts, often exhibit-
ing erratic, unreliable staining performance and according to one
study approximately half of all antigen-specific CD4+ T cells, espe-
cially self-antigens-specific ones, are not detected by conventional
multimers (29). Only in 2010 molecular defined pMHC II mul-
timers were described and their superior staining performance
demonstrated (30, 31) (Figure 1).
In 2000 “Pentamers” (by ProImmune) were introduced that
comprise five pMHC I complexes and five PE. Despite a lower
valency compared to conventional multimers, the staining perfor-
mance of both reagents seems to be similar (32). In 2002 meeting
the increasing need for sorting of antigen-specific CD8+ T cells
namely for in vitro studies or adoptive cell transfer experiments,
reversible multimers, based on biotin analogs, were introduced,
which allow sorting of untouched CD8+ T cells (33, 34). A third
type of reversible multimers, the NTAmers, based on multiva-
lent Ni2+-NTA-His-tag complexes, followed nearly a decade later
(35). In 2003 well-defined homologous pMHC dimers, tetramers,
and octamers were described that contained linkers of defined
lengths and configurations (36, 37). Binding and activation stud-
ies on cloned murine CTL and on CD8+ T cells from melanoma
patients revealed that the binding avidity and CD8+ T cell acti-
vation critically depends not only on the valence, but also on
pMHC–pMHC distances and configurations (38). In 2005 Dex-
tramers (by Immudex) were introduced, which consist of long
dextran fibers conjugated with multiple PE and pMHC I mole-
cules (39) (Figure 1). While these studies contributed to improve
analysis of antigen-specific T cells by means of pMHC oligomers,
only recent developments have substantially increased their use-
fulness for comprehensive immune monitoring. For example an
original new strategy allowing production of a wealth of different
pMHC I complexes was introduced in 2006, i.e., the UV irradia-
tion induced peptide exchange on pMHC I complexes containing
a photoreactive peptide (40). This technique is useful especially
for combinatorial multimer staining, independently established
by two groups in 2009 (41, 42). Combinatorial multimer staining
allows parallel detection of multiple specificities, which provides
more information on precious, often small blood samples. One
strategy uses binary color coding, i.e., antigen-specificity is defined
by a unique combination of two colors (41), whereas the other
strategy uses all possible color combinations, which affords higher
number of color combinations, but also stronger reduction in flu-
orescence intensity (42). Three years later CyTOF was introduced,
i.e., cytometry combined by time of flight measurements (43).
The cells are labeled with lanthanide labeled pMHC multimers,
resolved in a cytometer, converted in plasma, and its lanthanide
content analyzed by mass spectrometry. Presently about 30 chan-
nels, i.e., different mass tags, are available, which provides more
possibilities for parallel detection than flow cytometry (44). In
2012 also NTAmers were described, which are pMHC multimers
built on NTA-Ni2+-His-tag interactions that are nearly as sta-
ble as biotin–SA bonds, but upon addition of imidazole instantly
decay in their constituents. By using Cy5 labeled pMHC molecules,
NTAmers allow measurements of pMHC monomer dissociation
kinetics on CD8+ T cells (Figure 4).
WELL-DEFINED SOLUBLE pMHC COMPLEXES: TOOLS TO
STUDY CD8+ T CELLS LIGAND BINDING AND ACTIVATION
While most soluble pMHC complexes used for detection and iso-
lation of antigen-specific T cells are heterogeneous, complexes
of defined valence, configuration, and pMHC–pMHC distances
were made and tested on CD8+ T cells, which provided valuable
insights on how they bind and are activated by pMHC complexes
(Figure 2).
pMHC I MONOMERS
Due to the weak and transient nature of pMHC monomer binding
to CD8+ (and CD4+) T cells, on cells binding studies require spe-
cial techniques, such as TCR photoaffinity labeling (3, 19, 45, 46).
To this end CTL clones were derived from mice immunized with
a photoreactive derivative of the malaria circum sporozoite pep-
tide PbCS252–260 [SYIPSAEK(ABA)I, ABA: 4-azido-benzoic acid]
that specifically recognize this peptide derivative. These binding
studies on living CD8+ T cells revealed that the coreceptor CD8αβ
strongly strengthens TCR–pMHC interaction by coordinate bind-
ing to TCR-associated pMHC molecules (3). This increase in bind-
ing avidity varies in the range of 4- to 20-fold, depending of the
clone and temperature and was mainly accounted for by decreased
TCR–pMHC dissociation kinetics (45–47). The kinetics of pMHC
monomer binding on living CTL exhibited a prominent tempera-
ture dependence, namely a dramatic decreases of dissociation rates
with decreasing temperatures and biphasic association binding
kinetics at 37°C, but not in the cold (3). Soluble monomeric com-
plexes do not activate CD8+ T cells unless these are adhered
to a substrate; however, it was demonstrated that peptides of
soluble pMHC monomers can be transferred to CD8+ T cells
CTL-associated MHC I molecules by an unknown mechanism
and that this can engender CTL–CTL interactions (48, 49).
pMHC DIMERS
The first pMHC dimers described were fusion proteins consist-
ing of pMHC monomers fused to IgG and provided initial new
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FIGURE 2 | Role of valence and spacer distances of soluble pMHC
complexes on binding and activation of CD8+ T cells. (A) Cartoons of
mono, di, tetra, and octamer pMHC complexes, in which x and y indicate
maximal spacer distances in Å, X a pMHC monomer and SA streptavidin.
The spacer distances for the pMHC dimers varies from 18 to 90 Å. (B)
Relative binding on CD8+ T cells of monomer (black), short dimer (blue), and
long dimer (dotted blue). (C) Same as (B) with short tetramer (green), long
tetramer (dotted green), short octamer (red), and long octamer (dotted red).
Short distances are <20 Å and long distances are >80 Å. (D) Relative
activation (Ca2+ mobilization) of CD8+ T cells after binding of the
represented pMHC complexes. (E) Specific lysis of target cells (GP33
peptide sensitized P815/Db cells) was assessed following incubation with
LCMV d8 CD8+ CTL in the presence of Db/GP33 monomer (black bars) or
Db/GP33 long octamer (red bars). (F) Specific lysis of GP33 peptide
sensitized P815/Db cells was assessed in LCMV infected mice that were or
were not (LCMV) injected previously with octamer. Presented data were
derived from Ref. (36–38).
insights in pMHC dimer binding to CD8+ T cells, namely that
naïve, effector, and memory T cells exhibits substantially differ-
ent binding and activation/inactivation properties (24, 50). More
recently soluble pMHC I and II dimers were prepared that contain
synthetic linkers of different length and flexibility (37). Testing
of homologous Kd/PbCS(ABA) dimers containing linkers of 12–
130 Å showed that the binding avidity (K D) and the maximal
binding (Bmax) were maximal for very short cross-linkers and
gradually decreased with the spacer length of the linker to nearly
50% reduced K D and Bmax values at ≥80 Å (37) (Figure 2B).
Dimers containing short flexible linkers very strongly activated
CTL, which frequently induced CTL death via irreversible mito-
chondrial damages (38) (Figure 2D). By contrast dimers contain-
ing>80 Å long, rigid linkers induced no significant CTL activation
and were able to inhibit CTL activation (36). Moreover, pMHC I
(and II) mixed dimers were used to investigate the role of endoge-
nous pMHC complexes for T cell activation. Antigen-specific T
cell activation can be triggered by just a few cognate complexes,
but for this high sensitivity, endogenous complexes are needed
that although unable to trigger T cells by themselves, can substan-
tially boost T cell activation by a few cognate pMHC complexes
(51, 52). Conceptually it was proposed that such mixed pMHC
dimers, or by analogy vicinal pMHC complexes on antigen pre-
senting cells, promote coreceptor/lck association with TCR/CD3
and/or promote initial TCR/coreceptor co-aggregation on which
T cell activation relies (53).
pMHC TETRAMERS AND OCTAMERS
Conventional “tetramers” obtained by reacting biotinylated
pMHC monomers with PE (or APC) labeled streptavidin are het-
erogenous, and unable to dissociate completely from CD8+ T cells
(54). True tetrameric pMHC complexes can be prepared based
on tetra-grade PE-SA or SA labeled with low molecular weight
fluorochromes, e.g., Cy dyes. Real tetramers typically exhibit sub-
stantially lower binding avidities and fluorescence intensities, even
when PE is used as in the conventional multimers. Moreover, as
noted for pMHC dimers, tetramers containing short flexible link-
ers connecting pMHC to SA avidly bound to cloned CTL and
vigorously activated these, whereas those containing long (>80 Å)
rigid linkers bound less avidly, barely activated CTL and were able
to antagonize CTL activation (36) (Figures 2C,D).
Finally octameric complexes were prepared by reacting Cy5-
SA with Y shaped dimers in which two pMHC complexes were
connected via short flexible or long rigid linkers to a biotin
containing stem (36). Octamers composed of dimers with short
inter pMHC distances avidly bound to and activated cloned CTL,
whereas those consisting of dimers containing long rigid linkers
bound less avidly and barely activated CTL. Owing to their high
valence even octamers containing long rigid linkers exhibited avid
binding to CTL and were able to efficiently inhibit CTL killing
in vitro and in vivo and hence constitute a novel type of CD8+
T cell antagonists (36) (Figures 2C–F). Moreover, comparative
binding studies on Melan-A-specific CD8+ T cell clones derived
from a melanoma patient with A2/Melan-A dimers, tetramers,
octamers containing linkers of different length and flexibility
revealed striking differences depending on the state of CD8+ T
cell differentiation (55). In particular dimeric complexes contain-
ing a short linker avidly and selectively stained a population of
incompletely differentiation, dysfunctional CD8+ T cells, that are
typically observed in advanced melanoma patients, but never in
healthy individuals (55).
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SOLUBLE pMHC COMPLEXES BUILT ON NI2+-NTA–HIS-TAG
CHELATE COMPLEXES
THE MAKE AND NATURE OF REVERSIBLE pMHC COMPLEXES
Conventional BSP multimers are prepared by using the biotin–
streptavidin irreversible tandem. Although for some applications
this irreversible binding is desirable, for T cell staining it is not
as multimers can bind and strongly activate those cells, leading
sometimes to their death (Figure 3A). Nitrilotriacetic acid (NTA)
at neutral aqueous solutions chelates bivalent cations, e.g., Ni2+,
which in turn binds vicinal side chains of histidines. While the
monomeric interaction is in the micro-molar range, picomolar
dissociation constants were obtained for linear tetra-NTA com-
pounds binding to pMHC molecules containing a C-terminal
tandem His-tag (2xHis6) (35). While these coordination com-
plexes are stable, also at elevated temperatures, they decay within
a few seconds upon addition of free imidazole.
SORTING OF ANTIGEN-SPECIFIC T CELLS BY REVERSIBLE SOLUBLE
pMHC COMPLEXES
Although CTL are highly cytotoxic cells, they are remarkably sus-
ceptible to cell death, which can be induced by soluble pMHC
complexes, e.g., directly by Fas/FasL mediated cytotoxicity, mito-
chondrial damages due to excessive CTL activation, or indirectly
by fratricide caused by transfer of peptide from soluble to CTL-
associated MHC molecules (37, 56). To prevent this and functional
alterations, three types of reversible pMHC multimers have been
described (Figure 3B) that allow sorting of “untouched” antigen-
specific CD8+ (and CD4+) T cells (33–35, 57). Because T cell
activation and signaling takes place at physiological temperatures,
but not in the cold and pMHC monomers rapidly dissociate from
T cells, they are stained with the multimers and sorted by FACS or
MACS in the cold and cell-associated reagents are removed before
culturing the sorted cells at 37°C. Two reversible multimers are
built on altered biotin–SA scaffolds (33, 34, 57). The first ones,
called streptamers, which are commercially available from IBA
Life Science, consist of pMHC complexes containing C-terminal
one or two streptags, i.e., a linear peptide sequence that mimics
biotin and fluorescence labeled streptactin, a SA mutant that more
avidly binds sterptags than SA. Because the binding of one strep-
tag to streptactin is weak (micromolar range), it is advantageous
to use a tandem streptag for improved stability. While streptamers
(containing two streptags) in the cold are stable, decay becomes
appreciable at 20°C, which risks to affect their shelf life, especially
when brief periods of warming up cannot be excluded. The other
type of reversible multimer contains desthiobiotin (DTB) in place
of biotin, a biotin derivative with greatly weakened binding to SA
(33). As the streptamer, these multimers can be readily dissoci-
ated by addition of free biotin. These reagents are only stable in
the cold and readily decay at elevated temperatures, which can
be reduced when using two DTB per pMHC entity. A third type
of reversible pMHC multimers are NTAmer which being built
on Ni2+-NTA–His-tag chelates complexes, rapidly decay upon
addition of free imidazole (35). NTAmers built on NTA4-Ni2+-
tandem His6-tag are nearly as stable as biotin–SA multimers and
therefore are by far more stable than the other reversible multi-
mers, especially at elevated temperatures (Figure 3C). As described
below,multimer staining of antigen-specific CD4+ T cells is greatly
improved at elevated temperatures (18°C) and therefore for their
sorting NTAmers are recommended.
Sorting of antigen-specific CD8+ CTL with Streptamers or
NTAmers yielded fully functional CTL, whereas when conven-
tional tetramers were used their cytotoxicity and proliferation was
impaired (35, 57, 58). The cloning efficiency of NTAmer sorted
CTL was approximately twofold higher as compared to cloning
with conventional, irreversible multimers. Analysis of CTL clones
revealed that those preferentially lost by sorting with conventional
multimers exhibited high physical and functional avidity, which is
adverse in view of studies showing that high avidity CTL mediate
superior tumor control (59) (Figures 3D,E). The use of reversible
multimers thus is strongly recommended especially for sorting of
antigen-specific T cells used in immunotherapy.
ADDITIONAL APPLICATIONS FOR NTA-BASED REVERSIBLE SCAFFOLDS
PE-NTAmers allow detection of low avidity antigen-specific T cells
Previous pMHC binding studies on CD8+ T cells have revealed
that the binding avidity substantially increases at decreasing
pMHC–pMHC distances. In SA (and avidin derivatives) pMHC
built complexes the minimal inter distance is in excess of the
distance of their biotin binding sites (about 30 Å). By means of
site-specific alkylation, we conjugated PE with linear NTA pep-
tides and reacted this derivative with tandem His-tag carrying
pMHC complexes [(35) and unpublished data, Figures 4A–C].
Phycoerythrin, a saddle shaped molecule, about fourfold larger
than SA and with an abundance of surface lysines that permit the
preparation of PE–pMHC conjugates with smaller pMHC–pMHC
distances than in conventional multimers. The maximal degree of
conjugation is 12–16 pMHC complexes per PE, but the maximal
binding affinities were observed with conjugates containing 8–10
pMHC complexes per PE. Additionally these PE–pMHC NTAmers
are molecularly better defined than conventional multimers, as
they contain only one central PE, whereas conventional multi-
mers contain higher order conjugates. In accordance with this,
PE–pMHC NTAmer binding exhibit clear saturation and greatly
increased binding avidity compared to conventional pMHC mul-
timers and therefore can detect low avidity T cells that are missed
by conventional staining reagents (Figure 4D). Conclusive detec-
tion of low avidity T cells is one of the formidable challenges
in T cell monitoring, namely in cancer research where tumor
antigen-specific T cells tend to be low avidity due to deletion of
high affinity specificities by negative selection (60) and for CD4+
T cells, on which multimer binding is not strengthened by the
coreceptor.
NTAmers allow pMHC monomer dissociation kinetic measurements
NTAmer are not only substantially more stable than other
reversible pMHC multimers, but their induced dissociation is also
more rapid and therefore can be used to measure accurate pMHC
monomer dissociation kinetics on living CD8+ T cells (35). To this
end NTAmers are prepared with Cy5 labeled monomers. CD8+ T
cells are stained in the cold and the cell-associated PE and Cy5
fluorescences are measured before and after addition of imida-
zole (Figure 4E). After very rapid disintegration of the NTAmer,
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FIGURE 3 | Sorting of antigen-specificT cells with reversible pMHC
multimers. (A) Cartoon illustrating the principle of sorting of “untouched” T
cells. After cell staining and sorting, reversible, but not conventional
multimers can be removed and the T cells cultured at 37°C in the absence of
potentially harmful pMHC complexes. (B) Representation of the three types
of reversible bonds used for the preparation of pMHC oligomers and agent
used to provoke dissociation. (C) Flu matrix58–66 peptide stimulated PBMC
were stained at 4°C with A2/Flu multimers containing conventional
irreversible (red), NTA4-His (green), streptactin-streptag (orange), or
desthiobiotin–streptavidin (blue) scaffolds, washed and cell-associated
fluorescence measured after different periods of incubation at 20°C. (D)
Alternatively cells labeled with BSP (red) or NTAmer were FACS sorted and
cloned by limiting dilution. Hundred percent refers to the number of clones
obtained from BSP multimer sorted cells. (E) Randomly chosen clones were
incubated with BSP multimer at 37°C, stained with AnnexinV, and analyzed by
flow cytometry. Presented data were derived from (35).
reflected by rapid disappearance of PE fluorescence, pMHC
monomer dissociation from cells can be determined by from the
decrease of cell-associated Cy5 fluorescence. While dissociation
kinetics with pMHC multimers tend to be inaccurate due to
incomplete dissociation and heterogenous composition, pMHC
monomer dissociation reaches baseline and is more accurate
(Figures 4F,G). This technique is less sensitive than SPR measure-
ments, and inaccurate in the case of rapid kinetics, but provides
information on pMHC–TCR interactions on cells, namely in the
presence of CD8. Comparison of data obtained on a wide range of
TCR-transduced cells, with NTAmers or directly by SPR showed a
good correlation (unpublished data).
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FIGURE 4 | Peptide-MHC oligomers built on switchable Ni2+-NTA-His-tag
chelate complexes. (A,B) Cartoons illustrating conventional BSP multimers
pMHC (B) and reversible monomers directly coupled on PE via the NTA
strategy (A), where PE designates phycoerythrin. (C) The structure of a
phycoerythrin molecule is shown in which lysine side chains reacted with a
maleimido-N -hydroxysuccinimide ester and the resulting maleimido-PE will
subsequently reacted with thio-NTA derivative. (D) Room temperature
isotherms were shown for HLA-A2-Flu matrix58–66 BSP multimers (red circles)
or PE-NTAmer (green squares) as assessed on Flu peptide stimulated PBMC.
(E) Cartoon illustrating the two-step dissociation of PE labeled pMHC NTAmer
from T cells. Imidazole induced rapid decay of cell-associated NTAmers and
disappearance of PE fluorescence, followed by slower dissociation of Cy5
labeled blue monomers from the cells. (F) Cloned Flu matrix-specific CD8+ T
cells were stained in the cold with conventional A2/Flu58–66 PE multimers,
washed and cell-associated PE fluorescence measured by flow cytometry
after the indicated periods of time. (G) Alternatively the cells were labeled
with PE-NTAmers containing Cy5 conjugated A2/Flu58–66 monomers and the
monomer dissociation from the cells was assessed by flow cytometry as
illustrated in (E). The inserted numbers indicate the dissociation half-livesT 1/2.
Presented data were derived from (33) and (35).
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IMPROVED DETECTION AND ANALYSIS OF
ANTIGEN-SPECIFIC CD4+ T CELLS BY MOLECULARLY
DEFINED MHC CLASS II MULTIMERS
The performance of pMHC II multimers lags behind the one of
pMHC I multimers, in particular they often fail to detect low
avidity antigen-specific CD4+ T cells, which limits integral analy-
sis of CD4+ T cell responses. Factor accounting for poor pMHC
II multimer staining include (i) the coreceptor CD4, unlike CD8
fails to increase the pMHC binding avidity, (ii) certain types gly-
cosylation and sialylation of CD4+ T cell molecules, (iii) lower
affinity of MHC class II-peptide restricted TCRs, (iv) confor-
mational diversity of pMHC complexes, and (v) poor quality
of pMHC II multimers (61). While refolding of pMHC I com-
plexes provides highly pure monomers, production of pMHC II
monomers by loading of “empty” MHC II molecules with pep-
tides of interest does not and therefore the corresponding pMHC
multimers contain a reduced fraction of active monomeric com-
plexes. The fraction of correctly loaded pMHC II monomers
depends on the peptide and the MHC class II allele and can be
well below 50% (62, 63). Tethering the peptide on the MHC II
beta chain does not circumvent this caveat. Different strategies
were described that allow isolation of molecularly defined pMHC
II monomers. Peptide-MHC II tetramers containing defined frac-
tions of cognate and non-cognate monomers were used to inves-
tigate the dependence of pMHC II tetramer staining of CD4+ T
cells on pMHC II monomer purity. The efficiency of tetramer
staining of antigen-specific CD4+ T cells dependents on the
tetramer’s monomer purity; it decreases dramatically with the
monomer purity for low avidity CD4+ T cells, but much less
for high affinity cells. This explains why most successful pMHC
II tetramer staining reported thus far concerns pathogen-specific
CD4+ T cells and not tumor antigen-specific ones, which typi-
cally are of low avidity. The use of molecularly defined pMHC
II tetramers permits conclusive analysis of low avidity CD4+
T cells (64).
PEPTIDE-MHC II PRODUCTION
Soluble recombinant MHC II molecules typically consist of alpha
and beta chain where transmembrane and cytoplasmic domains
of which have been replaced by acidic and basic leucine zippers
(10). With very few exceptions soluble MHC II molecules are
expressed in insect cells, either stably in Drosophila Schneider cells
or transiently in sf9 cells using baculo virus (11, 61). Because in
insect cells there is no MHC II-peptide loading apparatus, nor any
retention mechanisms, they are typically secreted in“empty” form,
i.e., without a nominal peptide cargo (12). These soluble MHC II
molecules are purified usually be means of affinity chromatogra-
phy using anti-MHC II antibody columns (65). Even though this
provides highly pure MHC II proteins, the conditions used for
elution, such as extreme pH, are prone to cause partial denatura-
tion, which is an important factor for incomplete peptide loading
of “empty” MHC molecules. In order to circumvent this, soluble
pMHC molecules have been made containing a C-terminal His-
tag, which allows gentle affinity purification at neutral pH on
chelating columns, e.g., NTA or IDA columns. Loading of peptides
of interest onto“empty”pMHC molecules is usually accomplished
at reduced pH and elevated temperatures (e.g., pH 5.5–6, 30–37°C
for 24–72 h) and is on faith, i.e., without knowledge of the extent
of loading.
The peptide loading efficiency can be assessed by means of a
peptide tag, usually an N-terminal one, such as His-tag, dinitro-
phenyl (DNP), or biotin (31, 66, 67). Such studies indicated that
the degree of peptide loading can vary over a wide range and get as
low as 10–20%. In addition peptide tags allow isolation of correctly
loaded pMHC complexes, henceforth referred to as immunopure
pMHC complexes (31). While this is attractive it renders the syn-
thesis of pMHC class II multimers more tedious; importantly, the
addition peptide tags may affect CD4+ T cell antigen recognition
as suggested by observations that peptide truncations can have
significant effects on CD4+ T cell antigen recognition (68–70).
Therefore the use of conditional peptide tags would be desirable
and could be prepared similarly as conditional peptide ligands,
namely by linking it to the peptide via a photocleavable residue
such as 2-[2-nitro-phenyl]-propionic acid (71, 72).
An alternative strategy to prepare soluble pMHC monomers is
by tethering a peptide of interest to the N-terminus of the beta
chain via a long and flexible linker (10). This method allows the
preparation of murine pMHC class II monomers and tetramers,
which are difficult to obtain via peptide loading, as“empty” mouse
MHC II molecules are unstable. It is important to note that teth-
ered on peptides may or may not be properly nested in the MHC
II’s binding groove and that therefore the same concerns of denat-
uration, namely those related to immunoaffinity chromatography
are applicable as mentions above. Moreover, it has been reported
that depending on peptide truncations and linker length the teth-
ered on peptides may bind in different registers and hence be
differently recognized by antigen-specific CD4+ T cells (30, 62).
A major shortcoming of pMHC II tetramers is that they fail to
stain a fraction of antigen-specific CD4+ T cells (29). This is espe-
cially a concern for tumor and self-antigen-specific CD4+ T cells,
which tend to be of low avidity, due to deletion of high affinity cells
by thymic negative selection and much less for pathogen-specific
CD4+ T cells (29). This shortcoming curtails the usefulness of
pMHC II tetramers especially in research related to cancer or
autoimmunity (63, 73), because these fields of research become
increasingly more important, we review in the following sections
studies related to improving pMHC class II staining performance
especially on low avidity CD4+ T cells.
ON THE USE OF PEPTIDE TAGS TO ASSESS MHC II-PEPTIDE LOADING
AND TO ISOLATE IMMUNOPURE MONOMERS
In order to be able to measure peptide loading and to purify cor-
rectly loaded pMHC II complexes, several peptide tags have been
described; for example: (1) An N-terminal dinitrophenyl (DNP)
residue, allowing ELISA detection and isolation of DNP–pMHC
complexes by means of anti-DNP mAb. This technique is expen-
sive and addition of DNP renders poorly (Figure 5A) soluble pep-
tide completely water insoluble (74). (2) N-terminal His6-peptide
tags have been used that allow detection and isolation of specific
pMHC complexes by means of chelators, such as Ni2+-NTA or IDA
(31, 75). Advantages of this strategy include facile peptide synthe-
sis and improved solubility of peptides and inexpensive availability
of chelators for affinity chromatography and ELISA applications.
Disadvantages include (i) losses due to inadequate binding affinity,
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FIGURE 5 | Molecularly defined pMHC class II multimers detect low
avidity CD4+ T cells. (A,C,F) Cartoons illustrating the use of photocleavable
(red asterisk) peptide tags to discriminate pMHC II complexes containing
the peptide of interest (green ball) or irrelevant peptides (blue ball) (A), to
affinity purify correctly loaded complexes (C) and to remove the peptide
tag, either His6 or desthiobiotin that is linked to the peptide via a
β-nitrophenylglycine residue, which can be cleft by UV irradiation. (B)
“Empty” HLA-DR4 was incubated for 6, 24, and 48 h at 37°C at pH 6, 32°C
for 4 h with His6-HA306–318 (black bars) or His6-NY-ESO-1119–143 (white bars).
Peptide occupancy was calculated as (amount of His6-peptide bound to the
DR4)/(amount of total DR4). After gel-filtration the peptide occupancy was
determined by ELISA using affinity-purified complexes as reference (100%).
(D) Staining of DR52b/NY-ESO-1119–143-specific (top) or an irrelevant
(SSX2-specific) CD4+ T cell clone (bottom) were stained with 5.6 nM of
conventional (left) and “immunopure” DR52b/NY-ESO-1119–143 multimers
(right) at 37°C for 1 h and analyzed by flow cytometry. (E) Ex vivo CD4+ T
cells from PBMC of a DR52b+ healthy donors (HD) or of DR52b melanoma
patients either pre- or post-NY-ESO-1 vaccination were stained as in E plus
anti-CD45RA antibody and analyzed by flow cytometry. (G,H) The 37°C
binding isotherms of “immunopure” DR4/HA306–318 (blue) and conventional
multimers (red) on the DR4/HA306–318-specific clones 9 (G) or 8 (H). The
immunopure multimers contained [dark blue or not (light blue)] the
N-terminal His6-tag that was used for affinity purification. Presented data
were derived from (31).
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(ii) backgrounds due to non-specific co-ligation, and (iii) incom-
patibility with multimer formation based on His-tag-NTA chelate
complexes (35). (3) Biotin or desthiobiotin tag can be used for the
detection of specifically peptide loaded pMHC II-peptide com-
plexes. Disadvantages of these strategies include: (i) incompatibil-
ity with tetramer formation by means of biotin and streptavidin;
(ii) for affinity purification of specially peptide loaded pMHC
complexes, biotin binding tends to be too strong and DTB bind-
ing too weak (unpublished data); and (iii) aggravation of peptide
solubility problems by addition of biotin.
Previous studies with His6 or Cy5.5 tagged peptides revealed
that peptide loading to “empty” HLA-DR4 and DR52b molecules
is remarkably variable. As shown in Figure 5B the viral Flu HA
peptide bound to over 80% of “empty” DR4 molecules, whereas
the tumor antigen NY-ESO-1 peptide bound to only 20%. Similar
striking differences were observed for other viral and tumor anti-
gen derived epitopes on“empty”DR4, DR52b, and DP4 molecules,
with the viral peptides typically being the better binders. It may
be speculated that viruses that are older than adaptive immunity
of mammals, like the influenza virus, actively participated in the
evolutionary shaping of the MHC locus.
By means of an N-terminal His6-peptide tag and IDA chro-
matography immunopure DR52b/NY-ESO-1119–143 monomers
were produced and with these PE labeled multimers, which
exhibited dramatically improved staining a cloned ESO-specific
CD4+ T cells as compared to conventional DR52b/NY-ESO-
1119–143 multimers (Figures 5A,C–E) (31). More importantly,
these immunopure multimer allowed detection and detailed phe-
notypic and repertoire analysis of DR52b/NY-ESO-1119–143 spe-
cific CD4+ T cell in PBMC from melanoma patients post, but
not pre vaccination with NY-ESO-1 protein. In view of numer-
ous reports indicating that residues flanking the peptide binding
core sequence can sensibly affect their interaction with MHC class
II molecules, we established a procedure to remove the peptide
tag after affinity purification. To this end we used photocleav-
able 2-[2-nitro-phenyl]-propionic acid to link the His6-peptide
tag to the HA306–318 peptide, which allowed removing this tag
by UV irradiation at nanometers (Figure 5F). The photocleav-
age is rapid (∼4 min using a 45 W mercury fluorescence lamp
emitting at (365± 40 nm) and nearly quantitative (∼90%) (data
not shown). We then used this technique to prepare immunop-
ure DR4/HA306–318 multimers and compared their staining of
cloned, flu-specific CD4+ T cells before and after removal of the
His6-peptide tag. The multimer staining on one clone was mod-
estly higher when the His6-tag was present, but was unaffected
on another clone, indicating that this tag may affect pMHC II
binding and/or recognition on some, but not other CD4+ T cell
clones. What this experiment also shows is that the immunopure
multimers bind significantly more avidly than the conventional
multimer and that this difference is especially notable on low
avidity clones, which are not significantly detected by the normal
multimers (Figures 5G,H).
DETECTION LIMITS OF pMHC II MULTIMERS AND HOW THEY CAN BE
INCREASED
A major shortcoming of pMHC II multimers is their failure
to detect some antigen-specific CD4+ T cells. Studies using 2D
binding assays it has been shown that a substantial fraction of
antigen-specific CD4+ T cells responding in functional assays are
not detected by tetramer staining, but are visible in a 2D binding
assay (29). Interestingly comparison of CD4+ T cells specific for a
self versus viral antigens showed that the proportion of tetramer
undetectable CD4+ T cells is higher for the latter than the for-
mer. This is consistent with the view that for self-antigens CD4+
T cells expressing high affinity TCR are deleted by negative thymic
selection (76). It is important to note that the vast majority of
tumor antigens are self-antigens and that therefore tumor antigen-
specific CD4+ (and CD8+) T cell responses tend to be in average
of lower avidity than viral specific CD4+ T cells.
While on CD8+ T cells pMHC binding is substantially strength-
ened by coordinate binding of CD8 to TCR-associated pMHC
complexes, CD4 does not significantly contribute to pMHC bind-
ing (10). In addition, pMHC I complexes obtained by refolding
all contain the peptide of interest; because this is not the case
for pMHC II complexes obtained by loading of empty MHC II
molecules, CD4+ T cell tetramer staining can be compromised by
incomplete peptide loading. To investigate this, tetramers were
prepared that contained defined proportions of immunopure
cognate and non-cognate pMHC monomers. Using binominal
distribution the average contents of cognate pMHC II monomer,
dimer, trimer, and tetramer were calculated for different ratios
of cognate/non-cognate complexes used to make the tetramer
(Figure 6A); from these four different binding curves can be
calculated for the scenarios that a tetramer can stain a CD4+
T cell when it contains (1) one, two, three, or four or (2) two,
three, or four or (3) three and four or (4) only four cognate
monomers (Figure 6B). Staining of seven randomly chosen DR4-
restricted Flu HA306–318 specific CD4+ T cell clones (Figure 6C)
with tetramers containing graded fractions of cognate, immunop-
ure DR4-HA306–318 monomer, showed that such binding curves
are found, i.e., that clones can be grouped in different discrete
avidity ranges (Figures 6D–F). Importantly, this shows that low
avidity CD4+ T cells will not be detected by tetramer staining,
unless these contain only cognate pMHC monomers (Figure 6F).
In view of the fact that pMHC II tetramer staining risks to miss
a substantial fraction of antigen-specific CD4+ T cells, the use of
immunopure tetramers is highly recommended in order to detect
low avidity cells (Figures 6G,H).
The tetramer staining efficiency also critically depends on
CD4+ T cells surface glycosylation and pretreatment of cells with
a broadly active neuraminidase (e.g., from Vibrio cholerae) can
increase tetramer staining by nearly 100% (77, 78). Testing on 37
Flu-specific Th1 clones we found increases of tetramer staining
upon desialylation in the range of 20–95% (unpublished data).
CONCLUSION
Wide ranges of soluble pMHC I-peptide oligomers have been
prepared and used to analyze, activate, inactivate, and sort antigen-
specific CD8+ T cells. Well-defined pMHC dimers, tetramers, and
octamers containing linkers of defined length and flexibility were
instrumental in dissecting mechanisms governing pMHC bind-
ing by CD8+ T cells and the ensuing cell activation and eventual
cell death. Reversible multimeric pMHC complexes emerged as
useful reagents to sort “untouched” CD8+ T cells; of particular
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FIGURE 6 | Degree of peptide loading determines the avidity
detection threshold on pMHC II multimer detection. (A,B) Cognate
(DR4/HA306–318) and irrelevant (DR4/CLIP) pMHC II monomers were mixed
in different ratios (x -axis; fractions of one) and reacted with
streptavidin–PE to make tetramers. For 0, 20, 50, 80, and 100% of
cognate monomers the compositions of tetramers containing X =0, 1, 2,
3, or 4 cognate monomers were calculated according to the binominal
distribution and expressed in %, indicated by the inserted numbers (A),
with 100% being the sum of each row; alternatively it was plotted on the
y -axis as fraction of 1 against the fraction of cognate/non-cognate
complexes (x -axis) for the indicated four avidity levels T cell binding (red: all
four complexes bind; green: three; blue: two; and purple: one). (C) Seven
DR4/HA306–318-specific CD4+ T cell clones were incubated with 18.5 nM
DR4 tetramers with DR4 tetramers containing the indicated factions of
HA306–318 and CLIP peptides (x -axis; fraction of one) for 1 h at 37°C and
cell-associated fluorescence assessed by flow cytometry and expressed in
% of maximal binding (y -axis). (D–F) From these binding isotherms those
observed on the clones 11, 17, and 18 match the high avidity binding curve
(in red) (D), those recorded on the clones 19 and 20, match the green
curve (E) and the one measured on the clone 12 the purple curve (F).
(G,H) The cartoon representation of high (G) and low avidity (H) CD4+ T
cells as defined by their ability to bind mixed tetramers.
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interest were “switchable” NTAmer that additionally allowed mea-
surement of pMHC monomer dissociation kinetics on living cells
and detection of low avidity T cells. Detection of antigen-specific
CD4+ T cells by pMHC II multimers overall was more challenging
and prone to miss significant fractions of cells, namely low avidity
CD4+ T cells; detection of these cells was dramatically improved
by using molecularly defined multimers.
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